Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Monopar Therapeutics Inc.NASDAQ: MNPR
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$5.23M, compared with -$3.22M a year earlier. Trailing-twelve-month operating income was -$18.71M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -3.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.23M+15.1% QoQ
- Last fiscal yearDec 2025
- -$16.7M-3.4% YoY
- LTMMar 2026
- -$18.71M-5.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -62.2% | +100.0% | +162.2 pp |
| 1 year | -3.4% | +100.0% | +103.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (16.7M) USD
- Year-over-year change
- -3.4%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.7M) | -3.4% |
| FY2024 | 2024-12-31 | (16.16M) | -83.0% |
| FY2023 | 2023-12-31 | (8.83M) | +16.2% |
| FY2022 | 2022-12-31 | (10.54M) | -15.4% |
| FY2021 | 2021-12-31 | (9.13M) | — |
Operating Income vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.9% is the 8th highest of 11, against a peer median of +4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $44.15M USD | +162.5% | — | 16.6% | |
| LTM Jun 2026 | $9.56M USD | +121.6% | — | 27.2% | |
| LTM Mar 2026 | -$18.71M USD | -5.9% | — | — | |
| FY2025 | -€53.43M EUR | -3.6% | — | 1916.9% | |
| LTM Mar 2026 | -$63.66M USD | +36.0% | — | 40.5% | |
| LTM Mar 2026 | -$75.17M USD | -21.6% | — | — | |
| LTM Mar 2026 | -$91.17M USD | +33.2% | — | — | |
| LTM Mar 2026 | -$118.48M USD | +5.6% | — | 149.6% | |
| LTM Jun 2026 | -$216.08M USD | -69.5% | — | 205.8% | |
| LTM Mar 2026 | -$242.4M USD | +2.4% | — | 381.8% | |
| LTM Sep 2026 | -$300.69M USD | -28.4% | — | — | |
| Peer median (excluding MNPR) | — | +4.0% | — | 149.6% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.49M | 7.59M | 5.6M | 13.01M | 9.9B |
| Selling, General & Admin | 2.63M | 2.95M | 3.23M | 3.16M | 6.8B |
| Operating Expenses | 9.13M | 10.54M | 8.83M | 16.16M | 16.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.13M) | (10.54M) | (8.83M) | (16.16M) | (16.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24.02K | 21.24K | 429.04K | 404.02K | 2.99M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 24.02K | 21.24K | 429.04K | 575.3K | 2.99M |
| Income Before Tax | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.1M) | (10.52M) | (8.4M) | (15.59M) | (13.72M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| EPS (Diluted) | (0.73) | (0.83) | (0.58) | (1.36) | (1.85) |
| Weighted Avg Shares | 12.47M | 12.72M | 14.51M | 11.44M | 7.41M |
| Weighted Avg Shares (Diluted) | 12.47M | 12.72M | 14.51M | 11.48M | 7.41M |
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.